Business Segments and Geographic Information

The Company has five reportable segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.

Identifiable assets for the five principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its five reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and nine months ended June 30, 2018 and July 1, 2017. Segment information is as follows:



	Three Months Ended						Nine Months Ended
	June 30, 2018			July 1, 2017			June 30, 2018			July 1, 2017
Total revenues:
Diagnostics	$	294.2		$	284.1		$	858.5		$	905.4
Breast Health	307.9			283.7			896.0			837.4
Medical Aesthetics	91.7			110.0			268.5			126.1
GYN Surgical	107.7			106.5			314.7			322.4
Skeletal Health	22.5			21.8			66.8			64.6
	$	824.0		$	806.1		$	2,404.5		$	2,255.9
Income (loss) from operations:
Diagnostics	$	32.3		$	36.8		$	103.1		$	1,007.8
Breast Health	100.0			99.2			291.2			277.1
Medical Aesthetics	(22.2		)	(45.4		)	(805.3		)	(69.9		)
GYN Surgical	22.9			25.6			71.1			52.9
Skeletal Health	0.1			(1.2		)	3.0			(7.0		)
	$	133.1		$	115.0		$	(336.9	)	$	1,260.9
Depreciation and amortization:
Diagnostics	$	64.6		$	64.7		$	193.4		$	214.0
Breast Health	5.8			5.0			16.2			14.7
Medical Aesthetics	26.9			24.7			82.4			27.3
GYN Surgical	23.0			23.7			68.7			72.2
Skeletal Health	0.2			0.2			0.5			0.5
	$	120.5		$	118.3		$	361.2		$	328.7
Capital expenditures:
Diagnostics	$	12.8		$	13.0		$	38.7		$	34.7
Breast Health	4.5			3.2			11.8			7.2
Medical Aesthetics	1.6			3.3			6.7			3.7
GYN Surgical	2.5			3.5			8.2			10.9
Skeletal Health	1.3			0.2			2.1			0.5
Corporate	2.0			1.1			6.0			17.0
	$	24.7		$	24.3		$	73.5		$	74.0



	June 30, 2018		September 30, 2017
Identifiable assets:
Diagnostics	$	2,487.7	$	2,621.6
Breast Health	866.1		824.0
Medical Aesthetics	939.1		1,751.2
GYN Surgical	1,434.2		1,494.6
Skeletal Health	28.1		25.5
Corporate	1,336.2		1,262.7
	$	7,091.4	$	7,979.6

The Company had no customers that represented greater than 10% of consolidated revenues during the three and nine months ended June 30, 2018 and July 1, 2017.

The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.

Revenues by geography as a percentage of total revenues were as follows:



	Three Months Ended				Nine Months Ended
	June 30, 2018		July 1, 2017		June 30, 2018		July 1, 2017
United States	74.9	%	76.7	%	75.0	%	78.1	%
Europe	11.4	%	9.4	%	11.8	%	9.9	%
Asia-Pacific	9.0	%	8.7	%	8.5	%	7.9	%
Rest of World	4.7	%	5.2	%	4.7	%	4.1	%
	100.0	%	100.0	%	100.0	%	100.0	%